Juniper Pharmaceuticals, Inc. Common Stock
JNP
JNP was delisted on the 13th of August, 2018.
46 hedge funds and large institutions have $20.1M invested in Juniper Pharmaceuticals, Inc. Common Stock in 2016 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 14 increasing their positions, 15 reducing their positions, and 10 closing their positions.
4,075% more call options, than puts
Call options by funds: $167K | Put options by funds: $4K
7% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 15
10% less funds holding
Funds holding: 51 → 46 (-5)
21% less capital invested
Capital invested by funds: $25.5M → $20.1M (-$5.39M)
50% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$1.15M |
| 2 |
HA
Heartland Advisors
Milwaukee,
Wisconsin
|
+$747K |
| 3 |
Wells Fargo
San Francisco,
California
|
+$200K |
| 4 |
Renaissance Technologies
New York
|
+$109K |
| 5 |
TC
TFS Capital
West Chester,
Pennsylvania
|
+$97.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Cadence Capital Management
Boston,
Massachusetts
|
-$894K |
| 2 |
PCM
Perritt Capital Management
Chicago,
Illinois
|
-$570K |
| 3 |
WCM
Wedge Capital Management
Charlotte,
North Carolina
|
-$508K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$174K |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$138K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Group One Trading
Chicago,
Illinois
| – | -$43.6K | -6,597 | Closed |
|
|
TRCT
52
Tower Research Capital (TRC)
New York
| – | -$7K | -931 | Closed |
|
53
Citigroup
New York
| – | -$5K | -700 | Closed |
|
|
TWA
54
TCI Wealth Advisors
Tucson,
Arizona
| – | -$2K | -273 | Closed |
|
|
OSAM
55
O'Shaughnessy Asset Management
Stamford,
Connecticut
| – | -$1K | -98 | Closed |
|
JNP Hedge Fund Activity: Q3 2016 in Review
46 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Juniper Pharmaceuticals, Inc. Common Stock (JNP) for Q3 2016, worth a combined $20.1M — down 21% from $25.5M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of JNP and 5 opened new positions — a net loss of 5 holders — while 15 trimmed existing stakes and 14 added.
The largest buyer was Stonepine Capital Management, opening a new position worth an estimated $1.15M. The largest seller was Cadence Capital Management, exiting entirely with an estimated $894K sold.
- 46 institutional investors held Juniper Pharmaceuticals, Inc. Common Stock (JNP) as of Q3 2016, down from 51 in Q2 2016.
- Funds reported $20.1M of Juniper Pharmaceuticals, Inc. Common Stock stock for Q3 2016, down 21% quarter-over-quarter.
- 5 funds opened new Juniper Pharmaceuticals, Inc. Common Stock positions in Q3 2016 and 10 closed out, a net change of -5 holders.
- The largest Juniper Pharmaceuticals, Inc. Common Stock buyer in Q3 2016 was Stonepine Capital Management, an estimated $1.15M added.
- The largest Juniper Pharmaceuticals, Inc. Common Stock seller in Q3 2016 was Cadence Capital Management, an estimated $894K sold.
Based on aggregated 13F filings for Q3 2016.